View Information Collection Request (ICR) Package

Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.

View Generic ICR - OIRA Conclusion

OMB Control No: 0910-0810	ICR Reference No: 202308-0910-006
Status: Historical Active	Previous ICR Reference No: 202211-0910-008
Agency/Subagency: HHS/FDA	Agency Tracking No: CTP
Title: Generic Clearance for the Collection of Quantitative Data on Tobacco Products and Communications
Type of Information Collection: No material or nonsubstantive change to a currently approved collection	Common Form ICR: No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 08/22/2023
Retrieve Notice of Action (NOA)	Date Received in OIRA: 08/08/2023
Terms of Clearance: Previous terms continue: Approved consistent with the understanding that FDA will submit individual collections under this generic clearance to OMB. These submissions will include the actual study instruments along with a memo describing the specific study goal, the study design, any incentives to be used, and the sampling and analysis plans. Each IC request should include a justification for the chosen incentive (unless it is equivalent to or less than the pre-approved "standard" for focus groups ($75) and cognitive interviews ($40)). Further, FDA will send OMB an annual report summarizing the number of hours used, as well as the nature and results of the activities completed under this clearance.

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	12/31/2024	12/31/2024	12/31/2024
Responses	661,308	0	661,308
Time Burden (Hours)	91,865	0	91,865
Cost Burden (Dollars)	0	0	0

ICR Summary of Burden

	Total Approved	Previously Approved
Annual Number of Responses	661,308	661,308
Annual Time Burden (Hours)	91,865	91,865
Annual Cost Burden (Dollars)	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: The Food and Drug Administration is submitting this non-substantive change request to add a second year of data collection to the individual generic approval “Monthly Monitoring Study” (ICR Reference 201907-0910-006). The purpose of the Monthly Monitoring Study is to assess changes in vape use and perceptions. Given the evolving tobacco product landscape resulting from changes in product regulations, e-cigarette brand and flavor availability, and the COVID-19 pandemic which has impacted youth vaping, we would like to extend our data collection for another year to continue to track how these factors impact youth’s use and perceptions around vaping in order to inform future communication and educational initiatives. We estimate the burden to be identical for the second year to the first year. Therefore, we are doubling the previous estimate to cover the second-year burden. The new estimated total is 13,650 hours, an increase by 6,824 hours. There are no other changes to the collection.

Annual Cost to Federal Government: $525,239

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination. Yes

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination. No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? No

Agency Contact: Jonna Capezzuto 301 796-3794 jonnalynn.capezzuto@fda.hhs.gov